This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Scott E. Carlson, MD; Michael S. Aldrich, MD; Harry S. Greenberg, MD; Eric J. Topol, MD

Arch Neurol. 1988;45(10):1070-1073.

Abstract
• Tissue plasminogen activator's thrombolytic action is relatively specific for fibrin; however, systemic bleeding can occur in patients, especially when heparin is simultaneously administered. We describe two cases of intracerebral hemorrhage from a cohort of 450 patients (0.44%) treated at one institution with tissue plasminogen activator and heparin for acute myocardial infarction. A pooled worldwide review of 5258 cases from several clinical protocols for treatment of acute myocardial infarction, using tissue plasminogen activator from one source, revealed a similar overall incidence of 0.68%. The incidence of intracerebral hemorrhage may be reduced by lowering the total dose of tissue plasminogen activator or by reducing the infusion rate and duration. The incidence of central nervous system hemorrhage with tissue plasminogen activator is within the range reported with streptokinase, but because equal coronary artery thrombolytic doses are not known, no definitive comparison is possible.

Author Affiliations
From the Department of Neurology (Drs Carlson, Aldrich, and Greenberg), and Division of Cardiology, Department of Internal Medicine (Dr Topol), University of Michigan Medical Center, Ann Arbor.

Footnotes
Accepted for publication April 17, 1988.

Presented in part at the 40th annual meeting of the American Academy of Neurology, Cerebrovascular Disease Scientific Section, Cincinnati, April 19, 1988.

Reprint requests to Department of Neurology, 1920/0316 Taubman Center, 1500 E Medical Dr, Ann Arbor, MI 48109-0316 (Dr Aldrich).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage
Stewart et al.
Blood 2003;101:3002-3007.
ABSTRACT | FULL TEXT  

Old Microbleeds Are a Potential Risk Factor for Cerebral Bleeding After Ischemic Stroke: A Gradient-Echo T2*-Weighted Brain MRI Study
Nighoghossian et al.
Stroke 2002;33:735-742.
ABSTRACT | FULL TEXT  

Thrombolysis-Related Intracranial Hemorrhage : A Radiographic Analysis of 244 Cases From the GUSTO-1 Trial With Clinical Correlation
Gebel et al.
Stroke 1998;29:563-569.
ABSTRACT | FULL TEXT  

Prediction of Impending Hemorrhagic Transformation in Ischemic Stroke Using Magnetic Resonance Imaging in Rats • Editorial Comment
Knight et al.
Stroke 1998;29:144-151.
ABSTRACT | FULL TEXT  

Stroke After Thrombolysis : Mortality and Functional Outcomes in the GUSTO-I Trial
Gore et al.
Circulation 1995;92:2811-2818.
ABSTRACT | FULL TEXT  

Streptokinase and Recombinant Tissue Plasminogen Activator (rt-PA) Are Equally Effective in Treating Acute Myocardial Infarction
Sherry and Marder
ANN INTERN MED 1991;114:417-423.
ABSTRACT  

Streptokinase in the Treatment of an Acute Cerebral Embolus A Case Report
Frink and Ostrach
ANGIOLOGY 1990;41:66-69.
ABSTRACT  

Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator
Proner et al.
Arch Neurol 1990;47:105-106.
ABSTRACT  

Intracranial Hemorrhage after Use of Tissue Plasminogen Activator for Coronary Thrombolysis
Kase et al.
ANN INTERN MED 1990;112:17-21.
ABSTRACT